

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### ***APPLICATION NUMBER:***

**215422Orig1s000**

***Trade Name:*** LYVISPAH oral granules 5mg, 10 mg, 20 mg

***Generic or Proper Name:*** Baclofen

***Sponsor:*** Saol Therapeutics Research Limited

***Approval Date:*** November 22, 2021

***Indication:*** LYVISPAH (baclofen) oral granules is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.

LYVISPAH may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

# CENTER FOR DRUG EVALUATION AND RESEARCH

**215422Orig1s000**

## CONTENTS

|                                                           |
|-----------------------------------------------------------|
| <b>Reviews / Information Included in this NDA Review.</b> |
|-----------------------------------------------------------|

|                                                      |          |
|------------------------------------------------------|----------|
| <b>Approval Letter</b>                               | <b>X</b> |
| <b>Other Action Letters</b>                          |          |
| <b>Labeling</b>                                      | <b>X</b> |
| <b>REMS</b>                                          |          |
| <b>Summary Review</b>                                | <b>X</b> |
| <b>Officer/Employee List</b>                         | <b>X</b> |
| <b>Office Director Memo</b>                          |          |
| <b>Cross Discipline Team Leader Review</b>           |          |
| <b>Clinical Review(s)</b>                            | <b>X</b> |
| <b>Product Quality Review(s)</b>                     | <b>X</b> |
| <b>Non-Clinical Review(s)</b>                        | <b>X</b> |
| <b>Statistical Review(s)</b>                         |          |
| <b>Clinical Microbiology / Virology Review(s)</b>    |          |
| <b>Clinical Pharmacology Review(s)</b>               | <b>X</b> |
| <b>Other Reviews</b>                                 | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b> |          |
| <b>Proprietary Name Review(s)</b>                    | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>     |          |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**215422Orig1s000**

**APPROVAL LETTER**

NDA 215422

## NDA APPROVAL

Saol Therapeutics Research Limited  
Attention: Teri Robinson, PhD, PharmD  
Regulatory Manager  
1000 Holcomb Woods Parkway, Suite 270  
Roswell, GA 30076

Dear Dr. Robinson:

Please refer to your new drug application (NDA) dated January 22, 2021, received January 22, 2021, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lyvispah (baclofen) oral granules 5 mg, 10 mg, and 20 mg.

This NDA provides for the use of Lyvispah (baclofen) oral granules for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Lyvispah may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted November 19, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 215422.**” Approval of this submission by FDA is not required before the labeling is used.

## **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Lyvispah (baclofen) granules shall be 30 months from the date of manufacture when stored at 20°C – 25°C.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study(ies) requirement for ages less than 12 years of age because necessary studies are impossible or highly impracticable.

This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional pediatric studies are needed at this time.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication,

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup>  
Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Taura Holmes, PharmD, MS, Senior Regulatory Project Manager, at [Taura.Holmes@fda.hhs.gov](mailto:Taura.Holmes@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Teresa Buracchio, MD  
Director (Acting)  
Division of Neurology 1  
Office of Neuroscience  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

- Content of Labeling
  - o Prescribing Information
  - o Patient Package Insert
  - o Instructions for Use

---

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TERESA J BURACCHIO  
11/22/2021 04:46:54 PM